| Generic Name |
Avelumab |
| Brand Name |
Bavencio® |
| Payment Category |
Medicare Part B |
| Year Introduced |
2017 |
| Type of Drug |
PD-L1 blocking antibody |
| Manufacturer |
Pfizer, EMD Serono, Inc |
| Medical Affairs Questions (date verified) |
800.438.1985 |
| Coverage & Reimbursement Questions |
844.826.8371 |
| HCPCS |
J9023 |
| Billing Unit |
10 mg |
| Medicare Payment Limit (Effective January 1, 2021) |
$85.33 |
FDA-Approved Indication(s)
- Indicated for the treatment of 1) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma; 2a) maintenance treatment of patients with locally advanced or metastatic urothelial cancer (UC) that has not progressed with first-line platinum-containing chemotherapy, b) patients with locally advanced or metastatic UC who have disease progression following a platinum-containing chemotherapy, or c)Êpatients with locally advanced or metastatic UC whoÊhave disease progression within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; and 3) first-line treatment, in combination with axitinib, of patients with advanced renal cell carcinoma. (6/30/20)
|
| Approved Indication(s) with Orphan Drug Status |
Merkel cell carcinoma |
| ICD-10 Code(s) for Labeled Indication(s) |
Merkel cell carcinoma [C4A.xx]; Malignant neoplasm of ureter [C66.x]; Malignant neoplasm of bladder [C67.x]; Malignant neoplasm of other and unspecified urinary organs [C68.x] |
